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Abstract
Background: The study describes the molecular epidemiology of Streptococcus pneumoniae
causing invasive disease in Gambian children
Methods: One hundred and thirty-two S. pneumoniae isolates were recovered from children aged
2–29 months during the course of a pneumococcal conjugate vaccine trial conducted in The
Gambia of which 131 were characterized by serotyping, antibiotic susceptibility, BOX-PCR and
MLST.
Results: Twenty-nine different serotypes were identified; serotypes 14, 19A, 12F, 5, 23F, and 1
were common and accounted for 58.3% of all serotypes overall. MLST analysis showed 72 sequence
types (STs) of which 46 are novel. eBURST analysis using the stringent 6/7 identical loci definition,
grouped the isolates into 17 clonal complexes and 32 singletons. The population structure of the
8 serotype 1 isolates obtained from 4 vaccinated and 2 unvaccinated children were the same (ST
618) except that one (ST3336) of the isolates from an unvaccinated child had a novel ST which is
a single locus variant of ST 618.
Conclusion: We provide the first background data on the genetic structure of S. pneumoniae
causing IPD prior to PC7V use in The Gambia. This data will be important for assessing the impact
of PC7V in post-vaccine surveillance from The Gambia.
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Background
Pneumonia is a frequent cause of childhood deaths in
many developing countries and its leading cause is Strep-
tococcus pneumoniae [1-3]. In The Gambia, there is a high
burden of pneumococcal disease in young children in
both urban and rural settings [4-9]. During a recently con-
cluded pneumococcal conjugate vaccine trial in The Gam-
bia, the incidence of invasive pneumococcal disease in
children who had not received the vaccine was 363 (95%
CI 157, 715) per 100 000 person-years in children aged 6
weeks to 5 months and 576 (95%CI 369, 857) per 100,00
person years in those aged 6–11 months [7]. Similar fig-
ures have been reported from rural Kenya in a population
that had not received Hib or pneumococcal conjugate vac-
cines [10]. The pneumococcus is also a major cause of oti-
tis media, responsible for much morbidity in young
children worldwide [11]. HIV infection increases suscepti-
bility to pneumococcal infection and, as a consequence,
the incidence of pneumococcal infection in children and
adults is increasing in many parts of sub-Saharan Africa
[12,13]. Emergence of antibiotic resistant pneumococci
has complicated case-management strategies for pneumo-
coccal disease. Therefore, long-term prevention of pneu-
mococcal disease in young children by vaccination is a
major international public health priority.
S. pneumoniae is subdivided into 91 different serotypes
[14], all of which are capable of causing invasive disease.
Geographic variations in the distribution of pneumococ-
cal serotypes exist and some serotypes are associated selec-
tively with disease in children or adults [15]. The advent
of pneumococcal conjugate vaccines provides a potential
way of preventing pneumococcal disease although availa-
ble vaccines contain only a limited number of serotypes.
The results of a recently concluded efficacy trial of a 9-
valent pneumococcal conjugate vaccine (Wyeth) in Basse,
a typical rural African setting in The Gambia, are highly
encouraging as they showed protective efficacies, among
children who received three doses of vaccine according to
protocol, of 37% against radiological pneumonia, 77%
against invasive pneumococcal disease of vaccine sero-
type, 50% against overall pneumococcal disease, 15%
against all-cause hospitalizations and 16% against all-
cause mortality [16]. The licensed 7-valent pneumococcal
conjugate vaccine (Prevenar®) has had a dramatic impact
on the incidence of invasive pneumococcal disease in vac-
cinated infants in the United States and has also protected
unvaccinated adults through the induction of herd protec-
tion [17]. However, concerns have been raised about the
long terms effects of vaccines containing limited numbers
of serotypes on the overall pneumococcal population
[17]. Thus, prior to the planned introduction of PrevenarR
into the routine immunisation programme of The Gam-
bia, we studied 131 but presented data on 127 S. pneumo-
niae isolates obtained from vaccinated or unvaccinated
children (<2 years old) during The Gambian vaccine trial
(between August 2000 and April 2004) by BOX-PCR gen-
otyping and MLST to determine the current population
structure of pneumococci in the country.
Methods
Study population
Seven thousand, five-hundred and fifty-nine samples
including blood (6964), CSF (242), lung aspirate (123) or
pleural effusion (230) were obtained from 4,944 children
investigated for possible invasive pneumococcal disease
during the course of a 9-valent pneumococcal conjugate
vaccine trial (PCV9) conducted in The Gambia [7,16].
When more than one isolate was obtained during a single
episode of illness, for example from blood and CSF, mul-
tiple isolates have been included in the analysis only if
they differed by MLST and/or antibiotic susceptibility pat-
tern. Only one child had two episodes of illness. One
pneumococcal isolate was not viable after freezing and
has not been tested further. Consequently, 132 S. pneumo-
niae isolates were recovered from vaccinated and unvacci-
nated children aged 2–29 months during the course of a
pneumococcal conjugate vaccine trial conducted in The
Gambia of which 131 were characterized by serotyping,
antibiotic susceptibility, BOX-PCR and MLST and 127 had
unique MLST and/or antibiotic susceptibility pattern and
were included in this study. Details of how children were
enrolled, followed up and investigated have been
described previously [7,16]. Written consent was obtained
from the parents and the trial was approved by the Joint
Gambia Government and MRC Ethics Committee and
Ethics Committees at the London School of Hygiene &
Tropical Medicine and the World Health Organization.
Isolation and serotyping of S. pneumoniae
S. pneumoniae isolates were obtained from lung aspirate,
blood, CSF, pus or pleural fluid using an automated cul-
turing system and/or by direct plating onto solid blood
agar plates at the patient's bedside as previously described
[7,16]. Pneumococci were serotyped initially by latex
agglutination in The Gambia; serotype identification was
subsequently confirmed using capsular swelling
(Quellung reaction) at the Health Protection Agency
(HPA) laboratory in Colindale, UK, using commercially
available antisera (Statens Serum Institute, Copenhagen,
Denmark) as described previously [7,16].
Antimicrobial susceptibility testing
Antimicrobial susceptibility was determined by measure-
ment of the minimum inhibitory concentration (MIC).
MIC of each isolate was tested by E-strips (AB Biodisk,
Solna, Sweden) following the manufacturer's instructions.
The E-strips used tested for penicillin G, chloramphenicol,
ampicillin, tetracycline, cefotaxime and cotrimoxazole
sensitivity. S. pneumoniae ATCC 49619 strain was used as
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a control and data were interpreted as susceptible, inter-
mediate or resistant following the manufacturer's instruc-
tions.
The MRC microbiology laboratory submits to the external
quality assurance programme of the United Kingdom
National External Quality Assessment Service [18]
BOX PCR genotyping
Pneumococcal strain typing by BOX-PCR was performed
as described previously [19] with slight modifications.
Briefly, a single pneumococcal colony from a blood plate
instead of pure DNA was used as the template for PCR (40
cycles of 1 min at 94°C, 1 min at 55°C, and 1 min at
74°C). The amplified products were separated on a 1%
agarose gel and banding patterns were visualized with
ethidium bromide staining and UV illumination with a
gel documentation system (Gel Doc 2000; Bio-Rad, UK).
Multi locus sequencing typing (MLST)
S. pneumoniae isolates were streaked on blood agar and
incubated at 37°C for 18 hours. A single colony from each
isolate was picked, restreaked and incubated at 37°C for
18 hours. Genomic DNA templates were prepared from a
loopful of bacteria as described in the manufacturer's
instructions (Qiagen Genomic DNA Kit, UK). MLST was
performed as described [20]. The seven genes targeted
were aroE, gdh, gki, recP, spi, xpt and ddl. Amplifications for
all genes were carried out with approximately 0.2 μg DNA
template, 250 μM (each) deoxynucleoside triphosphates,
BOX-PCR fingerprint patterns of invasive paediatric S. pneumoniae isolates collected during the PVT trialFigure 1
BOX-PCR fingerprint patterns of invasive paediatric S. pneumoniae isolates collected during the PVT trial. (a) 
PCR fingerprint patterns generated with BOX primer. Lanes 2–10 contained serotypes found in the 9-valent vaccine (1, 4, 5, 
6B, 9V, 14, 18C, 19F & 23F) respectively. Lanes 1 &12 contained a molecular weight standard; 100-bp and 1 kb respectively. 
Lane 11; negative (no DNA) control. (b) BOX-PCR fingerprint patterns of invasive pneumococcal serotype 1 collected during 
the PVT trial. Lanes 2–9 &11 contained serotypes 1 isolates. Lane 1 contained a 1 kb molecular weight standard and lane 10 a 
negative (no DNA) control. There are two BOX-PCR fingerprint profiles designated A and B.
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2.5 mM MgCl2, 25 pmol of primers, and 1 U of Taq
polymerase (Qiagen.) in a 25 μl reaction mixture. PCR
cycling conditions were a 10 min hold at 94°C, followed
by 34 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C
for 1 min, and a final extension at 72°C for 5 min. Two μl
of reaction mixtures were separated by 1.0% agarose gel
electrophoresis and visualized with ethidium bromide
staining and UV illumination with a gel documentation
system (Gel Doc 2000; Bio-Rad, UK).
PCR products were sent to Macrogen (South Korea) for
purification and DNA sequencing on both strands.
Sequences were edited and complementary sense and
antisense fragments were aligned using the Laser Gene
DNA star 7.1 software. The sequences were submitted to
the MLST database website [21] and assigned existing or
novel allele type numbers and sequence type numbers
defined by the database. This multi microorganism data-
base defines a novel allele type if it contains one or more
nucleotide changes from existing allele sequences. Com-
posite sequence types (STs) are assigned based on the set
of allele types derived from each of the seven loci. STs
were analyzed for relatedness using the eBURST v3 pro-
gram [22]. Cluster analysis of allelic profiles was per-
formed using a categorical coefficient and a graphic
method called a minimum spanning tree with Bionumer-
ics software (version 4.0; Applied Maths, Sint-Martens-
Latem, Belgium).
Results
Microbiology
All 127 invasive isolates were screened for antimicrobial
susceptibility by disc diffusion and MIC was detected by
the E-test technique. 100% of the isolates were susceptible
to cefotaxime and ampicillin, whilst susceptibility to pen-
icillin, chloramphenicol, cotrimoxazole, and tetracycline
were 97.6%, 88.8%, 80.0% and 46.4% respectively. Two
isolates were resistant to three antibiotics (chlorampheni-
col, cotrimoxazole, and tetracycline) whereas 13 isolates
were resistant to two antibiotics (tetracycline and chlo-
ramphenicol or cotrimoxazole). One child had two epi-
sodes of pneumococcal disease caused by different
isolates. The isolate involved in the first episode of illness
was susceptible to all antibiotics tested whereas the isolate
from the second episode was resistant to tetracycline and
chloramphenicol.
Serotypes, clones and vaccination status
Twenty-nine different serotypes of pneumococci were
detected among 127 isolates (Table 1). Serotypes 14, 19A,
12F, 5, 23F and 1 (in descending order), were common
and accounted for 58.3% of all serotypes overall. Among
unvaccinated children, serotypes 14, 5, 23F, 12F, 19A and
9L (in descending order) were commonest. Overall, 59
(46.4%) of the 127 serotypes were covered by the conju-
gates in the PCV9 vaccine (Table 1).
The genetic structure of the 127 isolates was examined
using MLST and BOX-PCR analysis. BOX analysis revealed
that all the 127 isolates shared an identical or closely
related profile (representative isolates depicted in figure
1) and that this analysis can differentiate between sero-
types (figure 1a) and within serotypes (figures 1b). For
example we observed two fingerprinting patterns (A and
B) for serotype 1 isolates (figure 1b)
MLST showed that there were 72 sequence types (ST)
(Table 2), 46 (64%) of which are novel, i.e. not found in
the S. pneumoniae MLST database [21]. eBURST analysis
using the stringent 6/7 identical loci definition, grouped
these ST into 17 clonal complexes and 31 singletons indi-
cating a large genetic diversity between the isolates (figure
2). The results of cluster analysis of all allelic profiles
Table 1: Distribution of invasive paediatric S. pneumoniae isolates 
by vaccine and non-vaccine serotypes between children 
randomized to receive vaccine and those randomized to receive 
placebo (intent-to-treat analysis).
No. of isolates
Serotype Unvaccinated Vaccinated Total
1 3 5 8
2 1 0 1
4 3 0 3
5 10 1 11
6A 3 3 6
6B 4 1 5
8 0 2 2
9L 5 0 5
9V 2 2 4
12B 0 1 1
12F 7 5 12
14 17 3 20
16F 4 0 4
18C 1 0 1
18F 1 0 1
19A 6 6 12
19F 2 0 2
20 0 1 1
21 0 2 2
22A 1 1 2
23F 9 2 11
29 0 1 1
33F 0 2 2
35A 0 2 2
35B 0 1 1
38 2 0 2
40 0 1 1
45 1 0 1
46 0 3 3
Total 82 45 127
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using the minimum spanning tree are shown in figure 2.
In general, STs were restricted to the same serotype (Table
2) and the results between our data set and the pneumo-
coccal MLST database [21] were concordant.
A complete data set for BOX-PCR dendrogram, MLST,
serotyping, antibiotic susceptibility pattern and the source
of pneumococcal isolates used in this study are shown in
the figures 3 and 4'.
New alleles obtained in this study
We discovered seven new alleles including one aroE
(118), two gdh (188, 189), three spi (176, 178,179) and
one xpt (241).
Discussion
One hundred and thirty-two S. pneumoniae isolates were
recovered from vaccinated and unvaccinated children
aged 2–29 months during the course of a pneumococcal
conjugate vaccine trial conducted in The Gambia of which
131 were characterized by serotyping, antibiotic suscepti-
bility, BOX-PCR and MLST and 127 had unique MLST
and/or antibiotic susceptibility pattern and were included
in this study.-
There was no particular association of clones with specific
presentations of invasive pneumococcal disease (data not
shown) although three out of six (50%) cases of meningi-
tis were caused by pneumococci belonging to serotype
12F with ST989. This result concurs with findings in
Northern Ghana [23] and Niger where serotype 12F
ST989 isolates have been detected in patients with menin-
gitis. Serotype 12F ST989 isolates have also been identi-
fied in nasopharyngeal carriers in a village in Kenya [24]
and in Qatar [25]. Similarly, a SLV of ST989, serotype 12B
ST2211, was responsible for a case of meningitis in Niger
[25].
Clustering of STs by use of the minimum spanning treeFigure 2
Clustering of STs by use of the minimum spanning tree. Each circle represents an ST, and the serotype number is indi-
cated in the circle. The area of each circle corresponds to the number of isolates. Thick, short, solid lines connect single-locus 
variants and thin, longer, solid lines connect double-locus variants. Each colour represents the source of isolates. Source: LA 
(lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE (pleural effusion).
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Dendrogram showing the relatedness among the STs and serotypes of S. pneumoniae by use of UPGMA from BOX-PCRFigure 3
Dendrogram showing the relatedness among the STs and serotypes of S. pneumoniae by use of UPGMA from 
BOX-PCR. Notes: Antimicrobial patterns: pen (penicillin G); amp (ampicillin), chlo (chloramphenicol), cotr (cotrimoxa-
zole tetr (tetracycline) and cefo (cefotaxime); Source: LA (lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE 
(pleural effusion).
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Dendrogram showing the relatedness among the STs and serotypes of S. pneumoniae by use of UPGMA from BOX-PCRFigure 4
Dendrogram showing the relatedness among the STs and serotypes of S. pneumoniae by use of UPGMA from 
BOX-PCR. Notes: Antimicrobial patterns: pen (penicillin G); amp (ampicillin), chlo (chloramphenicol), cotr (cotrimoxa-
zole tetr (tetracycline) and cefo (cefotaxime); Source: LA (lung aspirate), CSF (cerebrospinal fluid), VB (venous blood), and PE 
(pleural effusion).
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In this study, we found twenty-nine different serotypes
corresponding to seventy-two MLST types (sequence
types). MLST is the definitive, internationally accepted
method for monitoring the spread of clones through the
pneumococcal population [20,21,26]. Our data showed
that serotype and genotype distribution varied considera-
bly in vaccinated and unvaccinated children suggesting a
high degree of fluidity in the pneumococcal population
dynamics (figure 2).
Although the 9-valent vaccine used in our trial contained
glycoproteins for serotypes 1 and 9V, pneumococci of
these serotypes caused a small number of cases of invasive
disease with no reduction in cases in vaccinated children.
For example, 4 vaccinated children (from whom 5 isolates
were obtained – Table 1) had invasive disease due to a
serotype 1 infection compared with 2 unvaccinated chil-
dren (from whom 3 isolates were obtained – Table 1).
There was no clustering of cases of serotype 1 in either vac-
cinated or unvaccinated groups over time during the
period 2002–2004. The very small number of serotype 1
and 9V cases detected precludes precise estimation of
serotype-specific efficacy for these two serotypes but these
findings raise the possibility that efficacy was lower
against serotypes 1 and 9V than against other vaccine-type
serotypes, despite the fact that the vaccine elicited strong
immune responses, as measured by ELISA, for all sero-
types contained in the 9-valent vaccine, including sero-
types 1 and 9V (data not shown). All but one of the seven
serotype 1 isolates in our study had the same genotype, ST
618. One of the isolates, from an unvaccinated child, had
a novel ST (ST3336) which is a SLV of ST 618. ST 618 and
its single and double locus variant have recently been
observed to cause meningitis in Ghana, Burkina Faso and
Egypt [25]. Furthermore, ST618 belongs to the same
clonal complex (ST 217) of serotype 1 that has caused an
outbreak of meningitis in Northern Ghana [23], indicat-
ing a dominant West African clone. The ST217 hyperviru-
lent clonal complex is typical of lineage B serotype 1
pneumococci that are predominant within Africa and
Israel [26]. A lower efficacy for serotype 1 and 9V could be
explained by heterogeneity or intraspecies variations
among these invasive pneumococci.
Isolates belonging to the same genotype (clone) can
express different types of capsular polysaccharide through
horizontal recombination of pneumococcal DNA by nat-
ural transformation [20]. This phenomenon, capsular
switching, leads to the emergence of a new clone express-
ing a different capsule [17]. There was no direct evidence
of capsular switching within our isolates. However, com-
parative analysis of our serotype and MLST results with
those published in the MLST database showed that some
genotypes found in our isolates express different serotypes
in other areas. For example, we found genotype ST63 to be
Table 2: Molecular characterisation of paediatric S. pneumoniae 
serotypes by MLST
Allelic profile
Serotype ST aroE gdh gki recP spi xpt ddl
Serotype 1 618 13 8 4 1 7 19 14
3336 13 8 4 1 7 19 161
Serotype 2 3314 2 13 4 1 6 6 6
Serotype 4 1469 8 88 103 18 46 142 161
3304 1 5 1 1 15 1 14
Serotype 5 289 16 12 9 1 41 33 33
3338 16 12 9 1 4 33 9
3404 16 12 9 1 176 33 33
3313 2 12 9 10 17 1 33
3339 16 12 9 1 41 33 9
Serotype 6A 912 6 57 34 28 7 1 9
913 6 57 83 28 7 19 9
1737 6 57 34 28 6 1 9
2157 1 8 1 5 42 60 14
3324 7 8 1 5 42 60 14
Serotype 6B 385 7 6 1 2 6 1 14
3342 60 82 4 5 42 122 28
3323 7 6 1 35 6 1 14
Serotype 8 3325 7 9 15 11 93 58 70
3406 7 9 15 11 178 58 70
Serotype 9L 1735 6 5 2 5 36 1 5
3305 1 8 4 15 16 3 31
3317 6 5 2 6 36 1 5
Serotype 9V 2179 15 17 4 4 6 1 17
3337 15 17 4 16 6 20 161
3409 15 17 4 4 179 20 17
Serotype 12F 989 12 5 89 8 6 112 14
Serotype 12B 3335 12 5 89 8 6 25 14
Serotype 14 63 2 5 36 12 17 21 14
3320 6 60 1 5 27 20 6
3312 2 5 89 12 27 21 14
3321 6 60 4 5 27 20 6
3333 10 60 4 12 15 112 6
3310 2 5 36 12 27 21 14
3318 6 9 4 5 27 20 6
3322 6 60 4 5 27 38 6
3309 2 5 36 12 17 38 14
3311 2 5 89 12 17 21 14
Serotype 16F 3341 23 12 4 1 6 12 74
3407 23 189 4 12 43 4 74
3408 23 189 4 12 15 241 74
3419 6 189 4 12 15 241 74
Serotype 18C 1233 10 11 34 16 15 1 145
Serotype 18F 2425 10 5 34 16 36 142 31
Serotype 19A 202 8 16 19 15 6 40 26
847 7 11 4 1 6 112 14
2174 7 16 8 8 6 142 14
3327 7 11 4 10 6 112 14
3326 7 11 4 1 6 112 15
3330 7 16 4 1 6 112 14
3315 5 6 1 2 6 1 5
3331 7 16 8 8 4 142 14
Serotype 19F 3307 2 5 4 10 6 1 14
3340 16 16 19 1 6 20 33
Serotype 20 1734 5 31 8 1 27 1 31
3316 6 5 2 5 67 49 18
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serotype 14 and associated with bacteremia and pneumo-
nia (figure 2) and ST63 serotype 14 is associated with
meningitis in Niger [27]. Elsewhere, ST63 has been found
to express serotype 15A, 19A and 23F capsular polysac-
charides [25], suggesting that ST63 has a high propensity
for capsular switching. ST912 expressing serotype 9V cap-
sular polysaccharide has previously been isolated from a
carrier in The Gambia [25] but in this study we found
ST912 expressing serotype 6A polysaccharide. Similarly,
ST2179 expressing serotype 6A capsular polysaccharide
has previously been isolated from a Gambian carrier [25]
while in this study we found ST2179 expressing serotype
9V polysaccharide and causing invasive disease, suggest-
ing capsular switching. Similarly, ST2174 expressing a
serotype 23F capsule has previously been isolated from a
carrier in The Gambia [25] but in this study we found
ST2174 expressing serotype 19A capsular polysaccharide
again suggesting capsular switching. This is plausible as
cluster analysis from our data shows that serotype 19A
and 23F are genetically linked (figure 2). Although our
data is suggestive that capsular switching can occur natu-
rally, a large dataset will be required to show the impact
of conjugate vaccination on this process. We have recently
set up nasopharyngeal pneumococcal carriage studies in
21 villages in The Gambia to address this question [28].
The use of PCV has the potential to reduce substantially
the number of drug-resistant pneumococcal infections
[29]. Antimicrobial resistance in pneumococci is closely
linked to serotype and genotype. Although we found no
penicillin resistant isolates in this study, there is evidence
from The Gambia that isolates of vaccine serotype have
significantly higher intermediate resistance to penicillin
than those of non-vaccine serotype (p < 0.01) [28]. Simi-
larly, isolates of 9-valent serotype were less likely to be
resistant to tetracycline than those of a non-vaccine sero-
type (39.0% vs. 52.6%; p < 0.05). In contrast, isolates of
non-vaccine serotype were more likely to be resistant to
chloramphenicol (p < 0.0001). Interestingly, we identi-
fied two serotype 6B isolates with ST385 and ST3323
which were-resistant to three antibiotics; chlorampheni-
col, cotrimoxazole and tetracycline. ST385 and ST3323
are also SLV and DLV respectively to ST273. ST273 is
known to be a major pandemic antimicrobial-resistant
clone, Greece 6B-22 [30,31] of pneumococci as defined by
the pneumococcal molecular epidemiology network.
Conclusion
Plans are being developed for the introduction of pneu-
mococcal conjugate vaccines into the routine immuniza-
tion programmes of several countries in Africa. We
conclude that in order to assess the impact of this inter-
vention on the prevalence of antimicrobial resistance in
strains of S. pneumoniae causing IPD and on the propen-
sity of PCV to cause serotype replacement it will be neces-
sary to monitor the antimicrobial susceptibility of S.
pneumoniae isolates from cases of IPD in parallel with
serotypic and genotypic characterization before and after
the introduction of these programmes.
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